Obesity

Eli Lilly's investigational triple agonist is already fueling gray-market sales and a $1 trillion valuation narrative ahead of its 2027 FDA filing.

Lilly opens early access to retatrutide for some patients before FDA approval, following scrutiny over a single earlier compassionate-use case.

GLP-1 use in adolescents and young adults with obesity rose to 96.1% as bariatric surgery fell by two-thirds, new JAMA Pediatrics data show.

Phase 3 TRANSCEND shows setmelanotide cuts BMI and hunger in acquired hypothalamic obesity, signaling a new targeted option after hypothalamic injury.

Expanded FDA indications and Medicare coverage of semaglutide for cardiovascular risk prevention were associated with increased Wegovy utilization, most notably through Medicare Part D.

Slated to run through December 31, 2027, the Medicare GLP-1 Bridge was originally supposed to run for only 6 months.

Those with class III obesity showed 7%+ weight loss with high engagement; Stephanie Kim, MD, MPH, talks GLP-1 complementarity and prospective study needs.

Adults with obesity using an AI-CGM platform lost weight nearly 3 times faster during engaged vs nonengaged periods (1.17% vs 0.44% per week).

Real-world data show AI coaching plus CGM helps adults with obesity lose up to 7% in 6 months, with engagement driving faster weekly weight loss.

Experts at ADA 2026 say nutrition guidelines must be personalized, culturally responsive, and built on research that reflects the patients they're meant to serve.

ACP's new obesity guidelines name semaglutide and tirzepatide as first-line drugs in a 4-tier hierarchy, with weight-regain warnings for all agents.

ADA 2026 spotlighted triple incretin therapy, intensive LDL lowering, and the equity gaps that keep advances from reaching all patients.

In this real-world study of patients with type 2 diabetes, treatment with semaglutide resulted in greater reductions in body weight and hemoglobin A1c than dulaglutide.

Medicare’s GLP-1 Bridge offers temporary coverage for obesity medication at $50/month, but patients face a 2027 cliff as BALANCE stalls.

Phenotype-based care improves childhood obesity diagnosis and treatment, including obesity types, hypothalamic obesity, drugs, and surgery.

A reproducible Prior Authorization Friction Index enables payers to identify glucagon-like peptide-1 delays and rework, reduce avoidable barriers, and monitor utilization, budgets, and equity in real-world practice.

Eli Lilly's triple agonist achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, matching bariatric surgery levels.

Most surveyed individuals with obesity support lower-cost options for weight maintenance, which would allow better coverage for injectable incretin mimetics for weight management during active weight loss.

Fatima Cody Stanford, MD, MPH, MPA, exposes obesity health disparities, GLP-1 access hurdles, payer policy fixes, and how stigma in care blocks equitable treatment.

Fatima Cody Stanford, MD, MPH, MPA, breaks down the brain mechanisms behind obesity and how to empower patients and improve clinical outcomes.

The results show that semaglutide could be a novel treatment for patients with alcohol use disorder moving forward.

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer coverage decisions are finally catching up.

A 2026 survey finds 2 in 3 employed adults would be more likely to use GLP-1 weight-loss drugs if employer coverage or behavioral support programs were available.

This retrospective analysis examines employees with obesity and reports on glucagon-like peptide-1 receptor agonist use, comorbidities, and work outcomes over time.

FDA approves Eli Lilly's orforglipron (Foundayo), the first GLP-1 obesity pill with no food or water restrictions.